Nonetheless, recent studies have demonstrated that pharmacologic inhibition of PI3K/AKT/mTOR signaling with rapamycin and its analogues is a potent cancer-selective therapeutic strategy for many tumor types. This evidence concerns the gene AKT1 and cancer.